A
Research grants
INHAPRO (KPOD.07.07-IW.07-0268/24)
INHAPRO Platform – Development of innovative anticancer biomolecules.
Funding period: 2024–2026; ABM
Grant value: 4 072 202.80 PLN
INHAPRO Platform – Development of innovative anticancer biomolecules.
Funding period: 2024–2026; ABM
Grant value: 4 072 202.80 PLN
Onco 3 (2022/ABM/05/00006)
Phase Ia/Ib clinical trial of a dual-mechanism anticancer fusion protein.
Funding period: 2022–2028, ABM
Grant value: 25 288 230.15 PLN
Phase Ia/Ib clinical trial of a dual-mechanism anticancer fusion protein.
Funding period: 2022–2028, ABM
Grant value: 25 288 230.15 PLN
VACCINE1 (2021/ABM/05/00001)
Development of novel mRNA/VLP-based vaccines against emerging zoonotic viral diseases.
Funding period: 2021–2026, ABM
Grant value: 57 996 213.54 PLN
Development of novel mRNA/VLP-based vaccines against emerging zoonotic viral diseases.
Funding period: 2021–2026, ABM
Grant value: 57 996 213.54 PLN
LABGEARS (RPLD.01.02.02-10-0052/19)
Development and implementation of an online application for R&D data management and analysis.
Funding period: 2020–2023, COP
Grant value: 1 534 820.30 PLN
Development and implementation of an online application for R&D data management and analysis.
Funding period: 2020–2023, COP
Grant value: 1 534 820.30 PLN
DILOC2 (POIR.01.01.01-00-0215/20-00)
Oral innovative drug for obesity and type 2 diabetes.
Funding period: 2020–2023, NCBR
Grant value: 19 152 038.67 PLN
Oral innovative drug for obesity and type 2 diabetes.
Funding period: 2020–2023, NCBR
Grant value: 19 152 038.67 PLN
ONCOTRAIL II (POIR.01.01.01-00-0220/20-00)
Preclinical and clinical development of a recombinant fusion protein for targeted anticancer therapy.
Funding period: 2020–2023, NCBR
Grant value: 18 088 028.60 PLN
Preclinical and clinical development of a recombinant fusion protein for targeted anticancer therapy.
Funding period: 2020–2023, NCBR
Grant value: 18 088 028.60 PLN
ONCO P53 KLINIKA (MAZOWSZE/0012/19-00)
Clinical development of an innovative anticancer compound acting via p53 activation.
Funding period: 2020–2023, NCBR
Grant value: 18 170 832.51 PLN
Clinical development of an innovative anticancer compound acting via p53 activation.
Funding period: 2020–2023, NCBR
Grant value: 18 170 832.51 PLN
BPSD (POIR/01.01.01-00-0108/17)
Development of drug candidates for the treatment of psychotic and cognitive disorders in dementia.
Funding period: 2017–2023, NCBR
Grant value: 25 796 383.65 PLN
Development of drug candidates for the treatment of psychotic and cognitive disorders in dementia.
Funding period: 2017–2023, NCBR
Grant value: 25 796 383.65 PLN
Publications
ONCOLOGY
Unraveling the Potential: mRNA Therapeutics in Oncology. Front Oncol 2025, 15, 1643444
In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III. International Journal of Molecular Sciences 2023, 24 (3), 2239
In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part II. International Journal of Molecular Sciences 2022, 23 (19), 11939
In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part I. International Journal of Molecular Sciences 2022, 23 (21), 12984
Activity and Rational Combinations of a Novel, Engineered Chimeric, TRAIL-Based Ligand in Diffuse Large B-Cell Lymphoma. Front. Oncol. 2022, 12
Ewolucja leków biologicznych w kontekście terapii onkologicznej. Onkologia w Praktyce Klinicznej – Edukacja 2020, 6 (1), 25–33
Novel Engineered TRAIL-Based Chimeric Protein Strongly Inhibits Tumor Growth and Bypasses TRAIL Resistance. International Journal of Cancer 2020, 147 (4), 1117–1130
The evolution of biologics in the context of oncological therapy. Oncology in Clinical Practice 2020, 16 (1), 14–21
Improved Cytotoxicity of Novel TRAIL Variants Produced as Recombinant Fusion Proteins. Protein Eng Des Sel 2018, 31 (2), 37-46
AD-O53.2—a Novel Recombinant Fusion Protein Combining the Activities of TRAIL/Apo2L and Smac/Diablo, Overcomes Resistance of Human Cancer Cells to TRAIL/Apo2L. Invest New Drugs 2014, 32 (6), 1155–1166
NEUROPSYCHIATRY
β-Arrestins as key Switches in GPCR signaling: from molecular structure to clinical implications – a narrative review.
Acta Poloniae Pharmaceutica– Drug Research 2025, Vol. 82 No. 4 pp. 545-562
Simultaneous Modulation of 5-HT6 and SERT by MM394: A Dual-Target Ligand Providing Neuroprotection against Amyloid-β Toxicity, Memory Preservation, and Alleviation of BPSD Symptoms. Pharmacol Biochem Behav 2025, 174128
Dual 5-HT6/SERT Ligands for Mitigating Neuropsychiatric Symptoms of Dementia Exerting Neuroprotection against Amyloid-β Toxicity, Memory Preservation, and Antidepressant-like Properties. Eur J Med Chem 2024, 275, 116601
Dual Molecules Targeting 5-HT6 and GABA-A Receptors as a New Approach to Combat Depression Associated with Neuroinflammation. ACS Chem Neurosci 2023, 14 (8), 1474–1489
Hybrid Molecules Combining GABA-A and Serotonin 5-HT6 Receptors Activity Designed to Tackle Neuroinflammation Associated with Depression. Eur J Med Chem 2023, 247, 115071
Metabolic and Cardiovascular Benefits and Risks of 4-Hydroxy Guanabenz Hydrochloride: Α2-Adrenoceptor and Trace Amine-Associated Receptor 1 Ligand. Pharmacol Rep 2023, 75 (5), 1211–1229
Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia. J Med Chem 2021, 64 (17), 12603–12629
Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates. CNS Drugs 2020, 34 (3), 243–268
Multifunctional 6-Fluoro-3-[3-(Pyrrolidin-1-Yl)Propyl]-1,2-Benzoxazoles Targeting Behavioral and Psychological Symptoms of Dementia (BPSD). Eur J Med Chem 2020, 191, 112149
INTERNAL MEDICINE
Design and biological evaluation of triagonist GLP-1R/GCGR/GIPR peptides as potential therapeutic agents for diabetes and obesity. RSC Med. Chem. 2026
In vitro activity of furazidin and comparator agents against bacterial isolates from urinary tract infections. Eur J Clin Microbiol Infect Disv 2026
Patents
PL244962
Anti-FOLR1 antibody and its application in medicine,
December 28, 2021
PL440011
Anti-FOLR1 nanobody and its application in medicine,
December 31, 2021
WO2019162306
Indole and Benzimidazole Derivatives as Dual 5-Ht2a and 5-Ht6 Receptor Antagonists,
August 29, 2019
WO2019141549
1,2,3’,5’-Tetrahydro-2’h-Spiro[Indole-3,1’-Pyrrolo[3,4-C]Pyrrole]-2,3’-Dione Compounds as Therapeutic Agents Activating Tp53, July 25, 2019
WO2018050808
Antineoplastic Fusion Protein,
March 22, 2018
WO2015189799
Compounds Comprising 1,1’,2,5’-Tetrahydrospiro[Indole-3,2’-Pyrrole]-2,5’-Dione System as Inhibitors P53-Mdm2 Protein-Protein Interaction, December 17, 2015
WO2015004610
1,5-Dihydropyrrol-2-One Derivatives as Inhibitors of P53-Mdm2/Mdm4 Protein-Protein Interaction, January 15, 2015
WO2013098755
Anticancer Fusion Protein,
July 4, 2013
WO2013080147
Anticancer Fusion Protein,
June 6, 2013
WO2012143477
Anticancer Fusion Protein,
October 26, 2012
WO2012093158
Anticancer Fusion Protein,
July 12, 2012
WO2012072815
Anticancer Fusion Protein,
June 7, 2012
WO2011161260
Anticancer Fusion Protein,
December 29, 2011